Annual EBIT
-$20.09 M
-$1.96 M-10.82%
31 December 2023
Summary:
Inhibikase Therapeutics annual earnings before interest & taxes is currently -$20.09 million, with the most recent change of -$1.96 million (-10.82%) on 31 December 2023. During the last 3 years, it has fallen by -$17.27 million (-612.78%). IKT annual EBIT is now -846.69% below its all-time high of -$2.12 million, reached on 31 December 2018.IKT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$5.83 M
-$777.00 K-15.38%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly earnings before interest & taxes is currently -$5.83 million, with the most recent change of -$777.00 thousand (-15.38%) on 30 September 2024. Over the past year, it has dropped by -$1.06 million (-22.20%). IKT quarterly EBIT is now -1307.95% below its all-time high of -$413.90 thousand, reached on 30 June 2020.IKT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$20.06 M
-$1.06 M-5.57%
30 September 2024
Summary:
Inhibikase Therapeutics TTM earnings before interest & taxes is currently -$20.06 million, with the most recent change of -$1.06 million (-5.57%) on 30 September 2024. Over the past year, it has dropped by -$42.80 thousand (-0.21%). IKT TTM EBIT is now -1057.96% below its all-time high of -$1.73 million, reached on 31 March 2019.IKT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.8% | -22.2% | -0.2% |
| 3 y3 years | -612.8% | -30.3% | -83.6% |
| 5 y5 years | -846.7% | -383.8% | -280.3% |
IKT EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -612.8% | at low | -34.4% | +6.0% | -83.6% | +0.5% |
| 5 y | 5 years | -846.7% | at low | -1308.0% | +6.0% | -883.6% | +0.5% |
| alltime | all time | -846.7% | at low | -1308.0% | +6.0% | -1058.0% | +0.5% |
Inhibikase Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.83 M(+15.4%) | -$20.06 M(+5.6%) |
| June 2024 | - | -$5.05 M(+5.6%) | -$19.01 M(-5.7%) |
| Mar 2024 | - | -$4.78 M(+8.6%) | -$20.16 M(+0.3%) |
| Dec 2023 | -$20.09 M(+10.8%) | -$4.40 M(-7.7%) | -$20.09 M(+0.3%) |
| Sept 2023 | - | -$4.77 M(-23.1%) | -$20.02 M(+1.3%) |
| June 2023 | - | -$6.20 M(+31.5%) | -$19.77 M(+8.6%) |
| Mar 2023 | - | -$4.71 M(+8.8%) | -$18.20 M(+0.4%) |
| Dec 2022 | -$18.13 M(+22.8%) | -$4.33 M(-3.9%) | -$18.13 M(-3.8%) |
| Sept 2022 | - | -$4.51 M(-2.7%) | -$18.84 M(+0.2%) |
| June 2022 | - | -$4.64 M(-0.0%) | -$18.79 M(+12.0%) |
| Mar 2022 | - | -$4.64 M(-8.0%) | -$16.78 M(+13.6%) |
| Dec 2021 | -$14.77 M | -$5.04 M(+12.8%) | -$14.77 M(+35.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$4.47 M(+70.1%) | -$10.93 M(+53.5%) |
| June 2021 | - | -$2.63 M(+0.1%) | -$7.12 M(+45.2%) |
| Mar 2021 | - | -$2.63 M(+118.6%) | -$4.90 M(+74.0%) |
| Dec 2020 | -$2.82 M(-50.5%) | -$1.20 M(+80.9%) | -$2.82 M(+38.2%) |
| Sept 2020 | - | -$663.70 K(+60.4%) | -$2.04 M(-21.0%) |
| June 2020 | - | -$413.90 K(-23.4%) | -$2.58 M(-42.7%) |
| Mar 2020 | - | -$540.00 K(+27.9%) | -$4.51 M(-20.9%) |
| Dec 2019 | -$5.70 M(+168.5%) | -$422.30 K(-64.9%) | -$5.70 M(+8.0%) |
| Sept 2019 | - | -$1.20 M(-48.5%) | -$5.28 M(+29.6%) |
| June 2019 | - | -$2.34 M(+35.0%) | -$4.07 M(+135.0%) |
| Mar 2019 | - | -$1.73 M | -$1.73 M |
| Dec 2018 | -$2.12 M | - | - |
FAQ
- What is Inhibikase Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual EBIT year-on-year change?
- What is Inhibikase Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly EBIT year-on-year change?
- What is Inhibikase Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM EBIT year-on-year change?
What is Inhibikase Therapeutics annual earnings before interest & taxes?
The current annual EBIT of IKT is -$20.09 M
What is the all time high annual EBIT for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual earnings before interest & taxes is -$2.12 M
What is Inhibikase Therapeutics annual EBIT year-on-year change?
Over the past year, IKT annual earnings before interest & taxes has changed by -$1.96 M (-10.82%)
What is Inhibikase Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of IKT is -$5.83 M
What is the all time high quarterly EBIT for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly earnings before interest & taxes is -$413.90 K
What is Inhibikase Therapeutics quarterly EBIT year-on-year change?
Over the past year, IKT quarterly earnings before interest & taxes has changed by -$1.06 M (-22.20%)
What is Inhibikase Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of IKT is -$20.06 M
What is the all time high TTM EBIT for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM earnings before interest & taxes is -$1.73 M
What is Inhibikase Therapeutics TTM EBIT year-on-year change?
Over the past year, IKT TTM earnings before interest & taxes has changed by -$42.80 K (-0.21%)